Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Recruiting Not applicable

Effect of High-Power Laser Therapy on Disc Morphology and Functional Outcome in Patients With Cervical Radiculopathy

NCT07661290 · tracked via the Priya Life Science Egypt tracker
Phase
Not applicable
Started
2026-07-10
Last updated
2026-07-07

Condition(s) studied

Radiculopathy

Investigational drug(s) / intervention(s)

High-Power Laser Therapy (HPLT)Ultrasound, Interferential Current, and Hot Packs

High-Power Laser Therapy (HPLT): High-Power Laser Therapy (HPLT): parameters Wavelength: 1064 nm Power output: 8-10 W Frequency: Pulsed wave (CW) Treatment Duration: 10-20 minutes per session Treatment Frequency: 3 sessions per week for 8 weeks (total of 24 sessions). Application: The laser is applied to the area of pain and nerve root compression, focusing on disc hydration, pain relief, and reduction of inflammation.

Ultrasound, Interferential Current, and Hot Packs: \- Ultrasound therapy: Frequency: 1 MHz (deep tissue penetration) Intensity: 1.5-2 W/cm² Duration: 8-10 minutes per session Application: Applied to the affected cervical region to enhance tissue healing and reduce pain and inflammation. \- Interferential current therapy: Frequency: 4,000 Hz (with a beat frequency of 80-150 Hz) Intensity: Adjusted to produce a comfortable muscle contraction without causing pain Duration: 10-15 minutes per session Application: Applied to the cervical region to reduce pain and improve circulation. \- Hot Packs: Temperature: 40°C - 45°C Duration: 15-20 minutes per session Application: Applied to the cervical region to promote muscle relaxation and alleviate discomfort.

Study summary

The study aims to evaluate the effectiveness of high-power laser therapy (HPLT) in patients with cervical radiculopathy, focusing on its impact on disc morphology, and overall functional activity

Eligibility

Sex
ALL
Min age
40 Years
Max age
60 Years
Healthy volunteers
No
Inclusion Criteria: \- Adults aged between 40 to 60 years. • A Body Mass Index (BMI) range of 18.5-35 (normal to overweight) will be required. • Diagnosed with cervical radiculopathy, confirmed by clinical examination and diagnostic imaging (e.g., MRI). • Pain intensity level of at least 4 on the Visual Analog Scale (VAS). • No previous history of surgery on the cervical spine. • Able to provide informed consent and participate in the study protocol. Exclusion Criteria: * Pregnant women or those planning to become pregnant. • Individuals with severe comorbidities that could interfere with the study, such as uncontrolled diabetes, cancer, or systemic inflammatory diseases. Individuals with severe cervical stenosis or spinal cord compression. • Individuals any form of malignancy, active infection, or dermatological issues on the neck. • Patients using opioid analgesics or other strong pain medications that could alter the results. • Previous treatment with high-power laser therapy within the last six months.

Primary outcome measure(s)

  • Disc height — 8 weeks
    Disc height: Measured using sagittal images, comparing the anterior and posterior heights of the cervical disc, height in meters.
  • Disc hydration — 8 weeks
    Disc hydration: Assessing changes in the signal intensity of the intervertebral disc, which indicates water content. This is typically measured on T2-weighted MRI sequences.
  • Disc protrusion — 8 weeks
    \- Disc protrusion: Examined using both sagittal and axial views to detect any changes in the disc's morphology, including the presence of herniation or bulging

Trial sites (1)

FacilityCityRegionStatus
Al Kasr Al Aini French Teaching Hospital Cairo Egypt Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07661290 on ClinicalTrials.gov ↗ ← All trials in Egypt